BiologicalDrug
Anti-CD19 CAR T Cells Preparation clinical trials
- studies test it
- 20
- open now
- 8
- in phase 3
- 0
- first study started
- 2015
Keep track of what changes. Save the Anti-CD19 CAR T Cells Preparation studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
20 studies that test it; most in 2016 (4)
| Year | Studies |
|---|---|
| 2015 | 1 |
| 2016 | 4 |
| 2017 | 1 |
| 2018 | 1 |
| 2020 | 2 |
| 2022 | 1 |
| 2023 | 2 |
| 2024 | 3 |
| 2025 | 2 |
| 2026 | 3 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 2
- Phase 1
- 17
- Phase 2
- 8
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 4 · Other 16
The Children's Hospital of Zhejiang University School of Medicine (3) · Yan'an Affiliated Hospital of Kunming Medical University (2) · Shanghai GeneChem Co., Ltd. (2) · PersonGen BioTherapeutics (Suzhou) Co., Ltd. (2) · Vinmec Research Institute of Stem Cell and Gene Technology (1) · Peking University Third Hospital (1) · Gustave Roussy, Cancer Campus, Grand Paris (1) · Sheba Medical Center (1)
Often tested with
Tested in the same studies.
Cyclophosphamide (1) · Anti-CD20 CAR T Cells Preparation (1)
Studies
Open first, then newest update. How each study uses Anti-CD19 CAR T Cells Preparation is read from its arms, and is right about nine times in ten.
Testing it · 20
- Safety and Efficacy of Universal CAR-T Cells (UWD-CD19) Combined With Immunosuppressants in the Treatment of Refractory Autoimmune DiseasesNot yet recruitingPhase 1/2Peking University Third HospitalNCT06821659Written as anti-CD19 CAR-T cells
- Study Investigating the Safety of Anti-CD19 CAR-T Cells Therapy Produced at Gustave Roussy for Adults With Severe and Refractory Systemic Autoimmune Rheumatic DiseasesNot yet recruitingPhase 1Gustave Roussy, Cancer Campus, Grand ParisNCT07544225Written as anti-CD19 CAR-T cells
- Pilot Study of Anti-CD19 Chimeric Antigen Receptor T Cells (CAR-T Cells) for the Treatment of Relapsed/Refractory CD19+ MalignanciesRecruitingPhase 1University of UtahNCT06227026Written as Anti-CD19 CAR-T cells
- Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin LymphomaRecruitingPhase 1C. Babis AndreadisNCT04545762Written as anti-CD19 CAR-T cells
- A Phase 1/2 Study of T-cell Expressing a Novel CD19 Chimeric-Antigen Receptor (SHB-02-CD19) in Patients With CD19-expressing B-cell MalignanciesNot yet recruitingPhase 1/2Sheba Medical CenterNCT07503353Written as SHB-02-CD19 (anti CD19 CAR-T cells)
- The Safety and Efficacy of Anti-CD19 CAR-T Cells in Patients With Relapsed/Refractory Autoimmune DiseasesNot yet recruitingEarly Phase 1First Affiliated Hospital of Wenzhou Medical UniversityNCT06420154Written as anti-CD19-CAR-T cells
- Anti-CD19-CAR-T Cells in Relapsed/Refractory B-cell Tumor Patients.RecruitingEarly Phase 1Shanghai Tongji Hospital, Tongji University School of MedicineNCT06375161Written as anti-CD19-CAR-T cells
- CD19-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory B-Lineage Leukaemia / Lymphoma - A Feasibility ProtocolRecruitingPhase 2KK Women's and Children's HospitalNCT05648019Written as Anti-CD19 CAR T-cells
- Clinical Study of CD19 CAR-T in the Treatment of Refractory Systemic SclerosisSuspendedPhase 1The Children's Hospital of Zhejiang University School of MedicineNCT06792344Written as anti-CD19 CAR-T cells
- Study of Therapeutic Efficacy of Anti-CD19 CAR-T Cell Therapy in Patients With MDR-SRNSWithdrawnPhase 1The Children's Hospital of Zhejiang University School of MedicineNCT06842589Written as anti-CD19 CAR-T cells
- Study of Therapeutic Efficacy of Anti-CD19 CAR-T Cells in Refractory Systemic Lupus ErythematosusActive, not recruitingPhase 1The Children's Hospital of Zhejiang University School of MedicineNCT06222853Written as anti-CD19-CAR-T cells
- CD19 CAR T-Cell Therapy for R/R Non-Hodgkin Lymphoma and Acute Lymphoblastic LeukemiaCompletedPhase 1Vinmec Research Institute of Stem Cell and Gene TechnologyNCT06027957Written as anti-CD19 CAR T-cells
- Anti-CD19 CAR in PiggyBac Transposon-Engineered T Cells for Relapsed/Refractory B-cell Lymphoma or B-cell Acute Lymphoblastic LeukemiaStatus unknownPhase 1Yan'an Affiliated Hospital of Kunming Medical UniversityNCT04289220Written as Anti-CD19 CAR-T Cells Injection
- CD19-targeting CAR T Cells for B Cell LymphomaWithdrawnPhase 1/2Fuda Cancer Hospital, GuangzhouNCT02547948Written as CD19-targeting CAR T Cells infusion
- CD19 CAR-T Cell Therapy for Relapsed/Refractory B-cell Lymphoma and B-cell Acute Lymphoblastic LeukemiaStatus unknownPhase 1Yan'an Affiliated Hospital of Kunming Medical UniversityNCT03854994Written as Anti-CD19 CAR-T Cells Injection
- A Study of CD19 Redirected Autologous T Cells for CD19 Positive Systemic Lupus Erythematosus (SLE)Status unknownPhase 1Shanghai GeneChem Co., Ltd.NCT03030976Written as anti-CD19-CAR-T cells
- CAR-T Cell Immunotherapy in CD19 Positive Relapsed or Refractory Leukemia and LymphomaStatus unknownPhase 1/2PersonGen BioTherapeutics (Suzhou) Co., Ltd.NCT02819583Written as PCAR-019 (anti-CD19 CAR-T cells)
- the Sequential Therapy of CD19-targeted and CD20-targeted CAR-T Cell Therapy for Diffuse Large B Cell Lymphoma(DLBCL)Status unknownPhase 1/2Southwest Hospital, ChinaNCT02737085Written as Anti-CD19 CAR-T cells and Anti-CD20 CAR-T cells
- Study Evaluating the Efficacy and Safety of PCAR-019 in CD19 Positive Relapsed or Refractory Leukemia and LymphomaStatus unknownPhase 1/2PersonGen BioTherapeutics (Suzhou) Co., Ltd.NCT02851589Written as PCAR-019 (anti-CD19 CAR-T cells)
- A Study to Assess CD19-targeted Immunotherapy T Cells in Patients With Relapsed or Refractory CD19+ B Cell LeukemiaStatus unknownPhase 1/2Shanghai GeneChem Co., Ltd.NCT02672501Written as anti-CD19-CAR-T cells